NPPA Fixes Retail Prices For 62 Formulations
The order specifies the retail prices for a total of 62 new drugs for specified strengths and manufacturers. These prices are exclusive of Goods and Services Tax, if applicable. Manufacturers are required to submit a price list in Form–V via IPDMS to the National Pharmaceutical Pricing Authority (NPPA) and provide copies to State Drug Controllers and dealers.
NPPA Revises Ceiling Prices for Chloroquine
NPPA has further increased the ceiling price of 1 Tablet of Chloroquine 150 mg from Rs. 1.17 to Rs. 1.33. The new prices take into account a minimal increase based on the Wholesale Price Index (WPI).
India Unveils Shorter, More Effective Treatment for Drug-Resistant Tuberculosis
The BPaLM regimen, a four-drug combination, offers a dramatic improvement over traditional MDR-TB treatments. While older methods can last up to 20 months with harsh side effects, the BPaLM regimen can cure drug-resistant TB in just six months with a high success rate.
Voluntary Recall Of Tisseel LYO Fibrin Sealant Kits
Healthcare providers may continue to safely use the products if the fibrin sealant is prepared in advance to ensure it is fully dissolved and ready to be used when needed. If the Sealer Protein Concentrate has not fully dissolved, discard the vial, and prepare a fresh kit. If a customer has unused Tisseel Fibrin Sealant Kits that they would like to return, they are requested to contact Baxter Healthcare Center for Service to arrange for return and credit.
Ayurveda Practitioners Warned Against Misleading Cannabis Claims
The National Commission for Indian Medicine (NCISM) has emphasized that registered medical practitioners should refrain from promoting themselves as cannabis specialists. Such claims can be misleading and could lead to the misuse of cannabis-containing drugs. It also observed that these drugs are being falsely advertised and prescribed for various ailments on online platforms.
CDSCO Publishes Not Of Standard Quality Alert For July 2024
The NSQ drug list specifies a total of 13 drugs that were detected to be deficient by State Lab Drugs Control Laboratory, Telangana. All of these 30 drugs were declared to be not of standard quality. The NSQ drug list for central CDSCO laboratories specifies a total of 57 drugs that were detected to be deficient.
Restrictions on Naproxen IP In Fixed Dose Combinations
The Central Government has restricted the manufacture, sale, and distribution of two fixed dose combinations (FDCs) containing Naproxen and either Esomeprazole Magnesium Trihydrate or Pantoprazole. The sale of these FDCs will be permitted only subject to specified conditions.
Prohibition of Manufacture, Sale and Distribution Of S(+)Etodolac + Paracetamol
The Drugs Technical Advisory Board (DTAB) was tasked with examining the necessity of prohibition of the FDC. After careful deliberation and considering the scientific evidence, the DTAB concluded that the FDC lacked therapeutic justification and posed potential risks to human health. This finding was instrumental in the government’s decision to impose a complete ban on the drug.
Government Seeks Public Feedback on Drug Distribution Practices
The Central Drugs Standard Organisation (CDSCO) is seeking public feedback on draft guidelines for Good Distribution Practices (GDP) for pharmaceutical products. These guidelines aim to ensure proper storage and handling of medicines throughout the supply chain, from manufacturers to retailers.
India Makes Strides in Bulk Drug Manufacturing
The Production Linked Incentive (PLI) scheme for promoting domestic manufacturing of key starting materials (KSMs), drug intermediates, and active pharmaceutical ingredients (APIs) was launched in 2022. A press release on the progress of the scheme was issued on August 9, 2024.
